Product Name:
JAK2
Product Number:
ab-nk085-3p
Target Full Name: Janus protein-tyrosine kinase 2
Target Alias: JAK-2; Janus kinase 2; JTK10; Kinase JAK2 ; JAK2_ENST00000381652; JAK2_ENST00000381652; CCDS6457; A8K910; A9QVL8; B4DYV1; Q506Q0; Q52R86; Q8IXP2; ENSG00000096968
Product Type Specific: JAK2 protein kinase pan-specific antibody
Antibody Code: NK085-3P
Antibody Target Type: Pan-specific
Protein UniProt: O60674
Protein SigNET: JAK2
Antibody Type: Polyclonal
Antibody Host Species: Rabbit
Antibody Immunogen Source: Human JAK2 sequence peptide Cat. No.: PE-01ARZ75
Antibody Immunogen Sequence: CDLALRVDQIRDNMAG
Antibody Immunogen Description: Corresponds to amino acid residues D1118 to G1132; Kinase last alpha-chain+C-terminus.
Production Method: The immunizing peptide was produced by solid phase synthesis on a multipep peptide synthesizer and purified by reverse-phase hplc chromatography. Purity was assessed by analytical hplc and the amino acid sequence confirmed by mass spectrometry analysis. This peptide was coupled to KLH prior to immunization into rabbits. New Zealand White rabbits were subcutaneously injected with KLH-coupled immunizing peptide every 4 weeks for 4 months. The sera from these animals was applied onto an agarose column to which the immunogen peptide was thio-linked. Antibody was eluted from the column with 0.1 M glycine, pH 2.5. Subsequently, the antibody solution was neutralized to pH 7.0 with saturated Tris.
Antibody Modification: Unconjugated. Contact KInexus if you are interest in having the antibody biotinylated or coupled with fluorescent dyes.
Antibody Concentration: 1 mg/ml
Storage Buffer: Phosphate buffered saline pH 7.4, 0.05% Thimerasol
Storage Conditions: For long term storage, keep frozen at -40°C or lower. Stock solution can be kept at +4°C for more than 3 months. Avoid repeated freeze-thaw cycles.
Product Use: Western blotting | Antibody microarray
Antibody Dilution Recommended: 1 µg/ml for immunoblotting
Antibody Potency: Medium immunoreactivity with recombinant human JAK2 on protein dot blots.
Antibody Species Reactivity: This antibody detects the target protein in the following species due to conservation of amino acid sequence: Human | Chimpanzee | Rhesus Macaque | Dog | Rat | Mouse | Chicken | Frog.
Antibody Positive Control: The observed molecular mass of the processed target protein on SDS-PAGE gels is reported to be around 125-135 kDa.
Antibody Specificity: High
Antibody Cross Reactivity: Weak immunoreactivity on protein dot blots with recombinant human JAK1, very weak immunoreactivity with JAK3, and no immunoreactivity with Tyk2.
Related Product 1: JAK2 (1118-1132) antibody blocking peptide (Cat. No.: PE-01ARZ75)
Related Product 2: JAK2Selectide kinase substrate peptide (Cat. No.: PE-01BHR90)
Related Product 3: JAK3Selectide kinase substrate peptide (Cat. No.: PE-01BHS95)
Related Product 4: IRS1 (891-902) KinSub kinase substrate peptide (Cat. No.: PE-01AQD95)
Related Product 5: JAK2 expression antibody (Cat. No.: AB-NK085-2)
Related Product 6: JAK2 expression antibody (Cat. No.: AB-NK085-3)
Related Product 7: JAK2 expression antibody (Cat. No.: AB-NK085-4)
Related Product 8: JAK2 Y1007+Y1008 phosphorylation antibody (Cat. No.: AB-PK667)
Related Product 9: JAK2 Y570 phosphorylation antibody (Cat. No.: AB-PK668)
Related Product 10: Tyk2 expression antibody (Cat. No.: AB-NK181-4)
Scientific Background: JAK2 is a protein-tyrosine kinase of the TK group and JAKA family. It is a non-receptor kinase involved in the regulation of various cellular processes, including cell cycle progression, development, differentiation, and histone modifications. Additionally, JAK2 plays a critical role in the signalling events of both innate and adaptive immunity as well as erythropoiesis. It features a FERM domain (receptor interaction), an SH2 domain (STAT binding), a pseudokinase domain (negative regulation), and a C-terminal tyrosine kinase domain (catalytic activity). The pseudokinase domain (JH2) normally acts as a brake, preventing the kinase domain from being constantly active. JAK2 can pair with type I receptors to mediate signalling for GHR (growth hormone), PRLR (prolactin), (LEPR) leptin, EPOR (erythropoietin), and THPO (thrombopoietin). JAK2 can also pair with type II receptors to mediate the effects of IFN-alpha, IFN-beta, IFN-gamma, and various interleukins. It is activated by phosphorylation at Tyr-613, and Tyr-972, and Tyr-1008. JAK2 signalling has been implicated in in a wide range of human hematologic malignancies, and this is typically accompanied by the over-activation of the STAT5 transcription factor, which is a substrate. Polycythemia vera, thrombocythemia, and myelofibrosis are classified as clonal myeloproliferative diseases that arise from a multipotent progenitor cell type. These often rare diseases are characterized by excess production of abnormal cells, displacing healthy cells. JAK2 is a known oncoprotein (OP). Cancer-related mutations in human tumours point to a gain of function of the protein kinase. A high percentage of patients with these myeloproliferative diseases have a dominant gain-of-function substitution mutation, V617F, in the JAK2 gene sequence. For example, the V617F mutation was observed in 40 of 45 polycythemia vera patients. The mutation was observed to cause constitutive tyrosine phosphotransferase activity that promoted erythrocytosis in a mouse model. The JAK2 V617F mutation is in the JH2 domain and causes the protein to be permanently turned on, preventing the cell from "turning off" signaling, leading to overproduction of blood cells. This description may include information annotated by UniProt and/or Google AI.